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Enrichment of rare circulating tumor cells (CTCs) in blood is typically achieved using antibodies to epithelial cell adhesion
molecule (EpCAM), with detection using cytokeratin (CK) antibodies. However, EpCAM and CK are not expressed in some
tumors and can be downregulated during epithelial-to-mesenchymal transition. A micro-ﬂuidic system, not limited to EpCAM
or CK, was developed to use multiple antibodies for capture followed by detection using CEE-Enhanced (CE), a novel in situ
staining method that ﬂuorescently labels the capture antibodies bound to CTCs. Higher recovery of CTCs was demonstrated using
antibody mixtures compared to anti-EpCAM. In addition, CK-positive breast cancer cells were found in 15 of 24 samples (63%;
range 1–60 CTCs), while all samples contained additional CE-positive cells (range 1–41; median = 11; P = .02). Thus, antibody
mixtures against a range of cell surface antigens enables capture of more CTCs than anti-EpCAM alone and CE staining enables
the detection of CK-negative CTCs.
1.Introduction
In order to analyze rare CTCs in the blood of cancer patients,
it is necessary to enrich, isolate and identify the tumor
cells in the presence of billions of red blood cells and the
tens of millions of nucleated hematopoietic cells. The most
commonly used form of enrichment relies on antibodies
against the epithelial cell adhesion molecule, EpCAM [1, 2].
The FDA-approved CellSearch system has set the standard
for the use of EpCAM in the enrichment of CTCs using a
magnetic ferroﬂuid approach [3, 4]. EpCAM is also used as
a main capture component in other immunomagnetic bead-
based systems as well as microﬂuidic systems [5–7]. Other
emerging approaches do not depend on immuoenrichment
at all but instead use precise size ﬁlters to separate larger
epithelial cells from smaller red blood cells (RBCs) and white
blood cells (WBCs) [8]. Alternatively, approaches using only
cell lysis to remove interfering RBC have been described
[9, 10]. In this case all remaining nucleated cells remaining
after RBC lysis are layered onto several slides for further
analysis. Systems using PCR for detection do not enumerate
based on visual cell detection, but still use immunomagnetic
beads coated with anti-EpCAM antibodies, among others,
for enrichment [7, 11, 12].
Regardlessofthesystemusedforisolationorenrichment,
detection almost always relies on staining for cells containing
cytokeratin, an internal architectural protein that is largely
associated with epithelial cells [13]. Most healthy control
blood contains few or no CK-positive cells [3]. Counter-
staining with anti-CD45 is employed to rule out occasional
nucleated WBC that stain for CK. In those cases where
EpCAM has not been used for enrichment, such as the
RBC lysis approach, EpCAM can alternatively be used for
detection[10,14].PCR-basedapproachesgenerallyusesome
combination of anti-EpCAM or anti-CK for enrichment or
detection before DNA is extracted for analysis [12, 15, 16].
Thus, there is a high dependence on just two epithelial
markers for capture and/or detection of CTCs.
Using the above criteria, it is implicitly understood that
the detection of CTCs is actually the detection of circulating2 Journal of Oncology
epithelial cells that are not typically present in blood, but
which can be detected as tumor-derived cells in the blood
of cancer patients. It has become axiomatic in the ﬁeld that
all CK and/or EPCAM positive, CD45-negative cells with a
nucleus in cancer patients are CTCs. A number of studies
using CellSearch have shown a good correlation between the
numbers of these circulating CK-positive/EpCAM-positive
cells and prognosis for cancer survival [17, 18]. There is
also considerable evidence that some of the CK-positive
cells contain cancer cytogenetic markers such as TMPRSS2-
ERG, MYC, PTEN, and Her2/neu [19–22]. The success
in correlating CTC enumeration with patient survival has
conferredadependenceonEpCAMandCKtovirtuallyevery
other system. This has also imposed a clear bias on the study
ofCTCs,primarilythefailuretoincludetumorcellsthathave
reduced or absent CK and/or EpCAM. The failure to identify
such cells limits investigations into additional tumor types.
EpCAM is expressed in most but not all tumors [23].
There is evidence for upregulation and down-regulation of
EpCAM with cancer progression and metastasis, and it is
likely that both are true, depending on the type and stage of
cancer and other biological variables not yet well understood
[24, 25]. CK is heterogeneously expressed in tumor, and
may be downregulated or secreted [26, 27]. During the
progression of epithelial-to-mesenchymal transition (EMT)
both EpCAM and CK are downregulated as part of an
oncogenic pathway to increased invasiveness and metastatic
potential [2]. EpCAM may be downregulated to allow
epithelial cell dissociation from the tumor, and the structural
cytoplasmic CK is downregulated to facilitate cell plasticity
and migration.
Given the potential range of genotypic etiology it may be
diﬃcultorimpossibletopredictthepredominantphenotype
of any given CTC in a sample. Signiﬁcant phenotypic
heterogeneity may exist between samples, or even among the
cells in a single sample. And yet the ﬁeld has been slow to
progress beyond the simple EpCAM capture, CK detection
modelbecausethereisnoclearalternative.Inordertoextend
the range of possible tumor cell enrichment it is necessary
to have a system with greater ﬂexibility to enrich and detect
additional types of CTCs.
In this study we report a platform that can be used
to simultaneously capture multiple circulating tumor cell
types by employing mixtures of antibodies that may include,
but are not solely dependent on, EpCAM. In addition, we
describe a novel universal staining method, CEE-Enhanced
that can selectively detect tumor cells that have been targeted
by the capture antibodies, regardless of their phenotypic
expression of other known cancer markers.
2.MaterialsandMethods
2.1. Blood Collection. Blood samples from cancer patients
were obtained from Conversant Biologics Inc., Huntsville,
Ala. All samples were collected using an IRB approved
protocol and informed consent. As controls, healthy donors
who had no history of cancer also provided informed
consent prior to participation. Blood samples were collected
into 10-mL Vacutainer tubes containing 1.5mL acid-citrate-
dextrose (ACD Solution A Vacutainers; Becton, Dickinson
and Company, Franklin Lakes, NJ.). Within 60 minutes of
blood collection, the addition of 250μL of anticlumping
reagent (CEE-Sure; Biocept, San Diego, Calif.) was injected
intoeachtubebeforebeing shippedtoBiocept forprocessing
within 24 hours of collection. Samples were stored at room
temperature (RT) before processing. v
2.2. Blood Sample Processing. Blood samples were initially
processedforrecoveryofperipheralbloodmononuclearcells
by using a Percoll density gradient method and Leucosep
tubes (Greiner Bio-One, Monroe, NC.). Each Leucosep tube
was preﬁlled with Percoll Plus (GE Healthcare, Piscataway,
NJ.)atadensityof1.083g/mL(adjustedusingnormalsaline)
and stored at RT. Each 10-mL blood sample was diluted
threefold with phosphate-buﬀered saline (PBS) containing
1mg/mL casein and 1mM ethylenediaminetetraacetic acid
(EDTA) and poured directly into a Leucosep tube. Samples
werecentrifugedfor15minutesat1000×gatRTinswinging
bucket rotors (Allegra X-12R centrifuge; Beckman Coulter,
Brea, Calif.), with brakes set to their lowest setting. After
centrifugation,theupperlayer(abovetheseparationbarrier)
was decanted through a 70-μm cell strainer into a 50-mL
conical tube. The decanted sample volume was adjusted to
45mL with PBS/casein/EDTA and then centrifuged for 10
minutes at 400×g. Supernatant was removed by aspiration.
The pellet was then resuspended and incubated with Fc
blocker (100μg/mL human IgG) and capture antibody
cocktail (each antibody adjusted to 1μg/mL) for 30 min-
utes at RT. After incubation, the pellet was washed by
adjusting the volume to 45mL with PBS/casein/EDTA and
centrifuging for 10 minutes at 400×ga tR T .B i o t i n y l a t e d
anti-mouse secondary (Jackson Labs, Bar Harbor, Me.) was
added to the pellet and after mixing, was incubated for
30 minutes at RT. The resulting pellet was washed three
times with PBS/casein/EDTA. Each wash step consisted
of centrifugation for 10 minutes at 400×g, followed by
supernatant aspiration. The ﬁnal pellet was suspended in
1mL PBS/BSA/EDTA and subjected to capture and staining
on the Cell Enrichment and Extraction (CEE) microchannel
(manufactured at Biocept, Inc., San Diego, Calif.). Samples
werepulledthroughCEEmicrochannelswithsyringepumps
(manufactured at Biocept Inc., San Diego, Calif.) connected
to the outlet at a volumetric ﬂow rate of 18μL/min. After the
entire sample was processed through the channel, cells were
cross-linked within CEE microchannels with 2mM NHS
homobifunctional protein cross-linker and ﬁxed with 80%
MeOH.
2.3. Antibody Mixture. Unless otherwise speciﬁed the cap-
ture antibody mixture contained the following individ-
ual antibodies: anti-EpCAM (Trop-1), tumor-associated
calcium signal transducer 2 (Trop-2), (BD Biosciences,
San Diego, Calif.); anti-c-MET (95106), anti-Folate-binding
protein receptor (MOV18), (R&D Systems, Minneapolis,
Minn.); anti-N-Cadherin (GC-4), (Sigma-Aldrich, St. Louis,Journal of Oncology 3
Mo.); anti-CD318 (CUB1), antimesenchymal stem cell anti-
gen (W305), anti-Her2 (24D2), (Biolegend, San Diego,
Calif.); anti-MUC-1 (M4H2) (Fitzgerald, Acton, Mass.); and
anti-EGFR (528) (Santa Cruz Biotechnology, Santa Cruz,
Calif).Eachantibodywasassessedbyﬂowcytometry(Accuri
Cytometers Inc., Ann Arbor, Mich) for positive signal on
multiple cultured cell lines, for example, SKOV (ovarian),
SKBR3 (breast), T24 (bladder), LNCaP (prostate), and for
l o wb a c k g r o u n do nb u ﬀy coat cells isolated from control
blood.
2.4. Microchannel and Detection of Captured CTCs on the
Microchannel. CEE microchannel design is illustrated in
Figure 1. The random size and spacing of the posts is
mathematically designed to avoid laminar ﬂow through
the channel, thus maximizing cell contact with the inner
surfaces.Theentireinnersurfaceofthechannelisderivatized
with tethered streptavidin and therefore cells may be specif-
ically bound on any surface. In practice the majority of the
CTCs are captured on the posts though some cells are found
on the channel ﬂoor.
Cells were stained with a mixture of anticytokeratin 7/17
(clone C-46), 18 (clone DA/7), 19 (clone A53-B/A2), and
pan-cytokeratin (clone C-11) (BioLegend, San Diego, Calif.)
antibodies labeled with AlexaFluor-488; CD45 antibody
(clone HI30) (BioLegend, San Diego, Calif.) labeled with
AlexaFluor-594for30minutes,washedwithPBSandstained
with DAPI III to visualize the nucleus. Channels were
stored at +8◦C until microscopic analysis. CTC enumeration
was performed by analysis through a standard Olympus
BX51 ﬂuorescence microscope (Olympus America Inc.,
Center Valley, Pa.) at 200 X magniﬁcations and based
on CK+/CD45-/DAPI+ stain criteria. The precise location
(X- and Y-stage coordinates) of each CTC was recorded,
permitting relocalization of cells after additional staining
procedures.
CE staining employed in situ labeling of captured cells
on the microchannel using 5μg/mL neutravidin labeled
with ﬂuorescent probes, including AlexaFluor 488 or 546
as indicated. Following initial scoring and localization of
CK+/CD45−/DAPI+ cells, the captured cells within the
microchannel were then subjected to CE staining whereupon
the channels were rescored to note the locations of the CE-
labeled cells as well as to assess presence of CE-stain on the
original CK stained cells.
2.5. Fluorescence in situ Hybridization (FISH). Following
CTC enumeration of the breast cancer samples in Figure 7,
the CEE microchannels were processed for multi-color FISH
using the FDA approved PathVysion HER-2 DNA Probe
Kit (centromere 17 speciﬁc probe (CEP 17-Spectrum Green)
and locus-speciﬁc HER2 probe (Spectrum orange)) and
a centromere-speciﬁc probe to chromosome 8 (CEP 8-
Spectrum Aqua, Abbott Molecular). Each of the micro-
channels was ﬁrst dehydrated before the addition of the
probe mixture. Codenaturation of the probe mixture was
performed on a ThermoBrite unit (Abbott Laboratories) at
95◦C followed by hybridization at 37◦C overnight. Postwash
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Figure 1: Diagram of the CEE microchannel. (a) Top view of
the channel showing the inlet where sample is loaded and the
outlet that is attached to a syringe pump to draw sample through
the channel. (b) Bottom view shows the area where 9,000 posts
are located in the silicone block and the channel sealed with the
bottom cover slip. The total volume of the microchannel is 24μL.
A standard microscope slide is added for stability during handling
but is removed to visualize cells. The microchannel is inverted on a
microscope and the captured cells viewed through the coverslip.
was performed at 74◦Ci n0 . 4 × saline-sodium citrate (SSC)
buﬀer containing 0.3% IPEGAL (Sigma-Aldrich, St. Louis,
MO.) followed by 2× SCC wash containing 0.1% IPEGAL
and then DAPI (blue). The CEE channels were imaged
on the Olympus BX51 ﬂuorescence microscope equipped
with ﬁlters to view DAPI, SpectrumAqua, SpectrumOrange,
and SpectrumGreen (Olympus America Inc.). Images
were analyzed with use of the ISIS imaging system v5.2
(Metasystems, Waltham, Mass.). Evaluation of FISH signal
patterns was performed on both CK-positive and CE-
positive cells in the microchannel. CTCs were identiﬁed. The
ratio of HER2:CEP 17 was calculated and a ratio >2.2 was
regarded as positive for HER2 gene ampliﬁcation.
3. Results
3.1. Microchannel Capture Eﬃciency Using Multiple Anti-
bodies. The eﬃciency of cell capture using immuno-based
systems is dependent on the presence and number of
surface antigens on the cells. Figure 2 shows the diﬀerence
in capture using T24 and SKOV cell lines when incubated
with either anti-EpCAM only and with a mixture of 24 Journal of Oncology
antibodies, anti-EpCAM and Trop-2. As determined by
ﬂow cytometry, T24 and SKOV cells had about 4,000 and
60,000 EpCAM antigens, respectively, and the inverse level
of Trop-2 antigens, about 60,000 and 12,000. The recovery
of T24 cells increases from 30% with anti-EpCAM only, to
90% when the cells were incubated with both anti-EpCAM
and Trop-2. SKOV cells were recovered at 80% with anti-
EpCAM and only marginally higher when Trop-2 was added.
Since antibodies in the current system serve to populate the
surface of the cells with biotin, these results demonstrate that
antibodies bound to the surface of the cells are additive with
respecttocaptureonthemicrochannel,andarenotmutually
exclusive.
Additional studies on SKOV cells further demonstrate
that while anti-EpCAM alone may be suﬃcient for good
capture,additionalantibodiesimprovedetectionwhenstain-
ing with CE. Figure 3 shows the capture of SKOV cells
with anti-EpCAM only and with a small antibody mixture
containing anti-Her2/neu, anti-CD44 and anti-CD26. Flow
cytometryshowedanaverageof66,000EpCAMantigensand
620,000 surface antigens using the mixture (Figure 3(b)).
Thereisnosigniﬁcantdiﬀerenceinthecellcapturewithanti-
EpCAM alone or with the antibody mixture (Figure 3(c)).
However, when SKOV cells incubated with anti-EpCAM-
only were stained using the CE protocol to label surface
antibodies, there was only faint staining, while the same cells
with multiply bound antigens had signiﬁcantly higher stain
intensity asshownwhenthecellswereviewedonmicroscope
slides (Figure 3(a)). This demonstrates that a mixture of
antibodies may not be needed to capture a given cell but the
extra antibody density on the surface of the cell signiﬁcantly
improves the staining intensity of the cell when using CE.
Cells on the microchannel were similarly detected using
either anti-CK or the CE protocol alone (discussed below).
3.2. Capture and Detection of CTCs. The immunostaining
intensity by CK or CE is based on the number of antigens.
For cell lines and many of the CTCs visualized in most
systems, CK staining is clearly visible by manual microscopy.
Single cells as well as small microemboli may be captured
in the microchannel (Figures 4(a)–4(c)) since the spacing
between the posts is suﬃcient to allow larger clumps of
cells to pass between the posts on the channel. However
there is a gradient of staining intensities in CTCs such that
some are not easily detectable above background. In those
cases where there is weak CK staining in a CD45-negative
cell, it may still be diﬃcult to distinguish a true positive
from background. The clinical example of this is seen in
Figure 5(a) which shows a CTC captured from a breast
cancer sample that was weakly CK positive. The location for
this cell on the microchannel was recorded and the cell was
relocated after subsequent staining with CE. In Figure 5(b)
the same cell was more intensely stained after treatment with
CE. This demonstrates that the cell was clearly captured
due to multiple capture antibodies on its surface, but the
endogenous CK itself was low or downregulated. Increased
staining intensity was routinely observed on weakly CK
positive cells. Figure 5(c) shows an SKOV cell spiked into
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Figure 2: Capture of T24 and SKOV cells spiked into blood. A:
the percentage capture of T24 cells using anti-EpCAM antibody.
B: T24 capture % using anti-EpCAM and TROP-2 antibodies. C:
SKOV capture % using anti-EpCAM antibody; D: SKOV capture %
using anti-EpCAM and TROP-2 antibodies. By FACS T24 cells were
shown to contain 4,000 and 60,000 EpCAM and TROP-2 antigens,
respectively; SKOV cells were shown to contain 66.000 and 12,000
EpCAMandTROP-2antigens,respectively.Antibodycaptureisless
eﬃcientwithlow-antigenexpressiononthecells,butincreasesinan
additive manner when antibodies are used in combination.
blood and captured on the microchannel with the antibody
mixture. CE only was used to detect this cell. The high
contrast image also shows the outline of the posts on the
channel. Background WBCs remain DAPI positive only.
Figure 5 shows that CTCs may be stained de novo with CE,
and that CE can also be used to enhance weakly stained CK-
positive cells.
Table 1 showsthecomparisonbetweencapturewithanti-
EpCAM alone and with an antibody mixture, as detected
with anti-CK stain. Duplicate tubes of blood from metastatic
cancer patients were incubated with anti-EpCAM only and
with the antibody mixture. On an individual basis, the eﬀect
of using an antibody mixture can range from no increase in
CK-positive cells to severalfold higher. Overall, the antibody
mixture captured signiﬁcantly more CK-positive cells than
anti-EpCAM alone (mean 18.5 versus 26.5, paired t-test
P = .02). Since the distribution of these results was
nonparametric, the paired Wilcoxon test was used and
showed a median of 6 with anti-EpCAM versus 12 CK-
detected cells with the antibody mixture (P = .02).
Table 2 shows the additive nature of CTCs captured
on the microchannel under diﬀerent capture and staining
conditions. Two tubes of blood were collected from each
patient, and capture tested with either anti-EpCAM alone or
with the antibody mixture containing anti-EpCAM, unless
otherwise speciﬁed. The captured cells on the microchannel
were initially stained and scored for the presence of CK and
CD45, and then stained and scored for CE. The general trend
as shown in Table 2 was that an antibody mixture generally
captured more classically deﬁned DAPI+/CK+/CD45− cells
than anti-EpCAM alone, and that CE revealed more cells
than did anti-CK. However, the heterogeneity of cells within
samples is apparent even in this small cohort in that the
percentage increase in diﬀerent samples is quite variable.Journal of Oncology 5
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Figure 3: Capture and stain of SKOV cells with EpCAM and with
an antibody mixture. (a) The relative stain intensity of these cells
on a microscope slide using anti-mouse-AlexaFluor488 when the
cells were preincubated with anti-EpCAM antibody only, or with
an antibody mixture of anti-HER2/neu, anti-CD44 and anti-CD28.
(b) The FACS proﬁle of the respective antigens of EpCAM or of the
3-antibody mixture present on each cell. (c) The percentage capture
ofSKOVcellswhenpreincubatedwithanti-EpCAMortheantibody
mixture. This shows that much lower antigen levels are necessary
for good cell capture than for good staining intensity. Antibody
mixtures improve CE staining eﬃciency.
In two of the prostate samples, a third tube of matched
blood was obtained and incubated with the same antibody
mixture except that anti-EpCAM was omitted. The capture
was comparable to the antibody mixture containing anti-
EpCAM on prostate samples containing both high and low
levels of endogenous CTCs. This suggests that there was
an abundance of additional antibodies other than EpCAM
boundtothesurfaceofthesecells.Thisisalsoconsistentwith
increased capture using the antibody mixture since there
are CTCs present that do not contain EpCAM (Table 1).
The antibody mixture without anti-EpCAM captured more
Table 1: Comparison of the number of CK-positive CTCs
detected with anti-EpCAM-only and with an antibody mixture (see
Section 2).
Tumor type Anti-EpCAM only Antibody mix
Breast 0 1
Prostate 37 33
Breast 8 25
Lung 0 0
Breast 8 12
Breast 94 115
Breast 0 1
Prostate 57 97
Prostate 0 0
Colorectal 0 1
Breast 6 16
Lung 1 2
Breast 13 22
Breast 54 72
Breast 0 0
Breast 0 1
cells than anti-EpCam alone, consistent with the presense of
EpCAM-negative cells.
Table 2 further illustrates that there are EpCAM-positive
cells that are captured but lack detectable levels of CK. These
cells only become visible when anti-EpCAM-captured cells
arestainedwithCE.Inthiscase,CEislabelingonlycellswith
bound anti-EpCAM since this is the only antibody used for
capture.TheantibodymixtureshowedthehighestlevelofCE
staining as might be expected. While the antibody mixture
showed modestly higher CK-stained cells, signiﬁcantly more
CE cells were detected in all cases, indicating that the
antibody mixture was binding to many more CK negative
cells than was anti-EpCAM alone. All positive CK or CE cells
were CD45 negative.
Dual staining was used to show simultaneous detection
using anti-CK and CE. CTCs were captured with the
antibody mixture followed by anti-CK (Figures 6(a) and
6(d), labeled with AlexaFluor488, green ﬂuorescence) and
then CE (Figures 6(b) and 6(e), labeled with AlexaFluor
546; orange ﬂuorescence). Figures 6(c) and 6(f) are color
composite images. Figures 6(d)–6(f) show, an image of two
attachedCTCswhileA–Cisasinglecellonthemicrochannel.
All relocated DAPI+/CK+/CD45− cells became dual positive
for green (CK) and orange (CE). Figure 6 conﬁrms that CK
positive cells are simultaneously labeled with CE. The anti-
CK intensity can be augmented with a single color as shown
in Figure 5(b) or the CTC can be dual stained with anti-CK
and CE having two diﬀerent ﬂuorescent dyes.
Figure 7 shows CTCs isolated from a serial set of stage
IV breast cancer samples using the antibody mixture for
capture. Captured CTCs were ﬁrst stained with anti-CK,
scored, and then stained with CE. The dark bars show the
number of CK-positive cells detected and in each case the
light bars stacked on top of the dark bars show the additional
cellsdetectedwithCE.Fifteenof24samples(63%)contained6 Journal of Oncology
(a) (b) (c)
Figure 4: Immunoﬂuorescent staining. (a) A LnCAP cell spiked into blood and captured on the microchannel, stained for CK (green) and
also nuclear stained with DAPI (blue). A small WBC is seen with only the nucleus stained blue. (b) A cluster of CTCs from a clinical lung
cancer sample captured on the microchannel that are stained for CK. These cells were CD45-negative and DAPI-positive (not shown). (c) A
cluster of cells from lung cancer showing triple staining with CK (green), CD45 (red), and DAPI (blue). Three CK-positive CTCs are shown
with 2 smaller WBCs stained positive for CD45.
Table 2:ComparisonofthenumberofCTCscapturedusingsingleandmultipleantibodies,anddetectedusinganti-CKandCEE-Enhanced.
Cancer type Anti-EpCAM Antibody mix Anti-EpCAM Antibody mix
Cytokeratin stain Additional CTCs detected with CEE-Enhanced stainb
Small Cell Lung Cancer 24 47 +151 +148
Prostate 127 200 (162a)+ 4 9 + 6 1
Prostate 2 5 (7a)+ 1 1 + 2 7
Prosate 12 10 +2 +25
Colorectal 1 +4
aA third tube of matched blood was processed using the antibody mixture that did not contain anti-EpCAM.
bAll cells were CD45-negative and DAPI-positive.
CK-positive cells (range 1–60 CTCs) while all of the samples
contained at least one additional CE-positive cell (range 1–
41; median = 11; Wilcoxon test, P = .02). The correlation
coeﬃcient (r = 0.57, P = .004) suggests a weak correlation
between CK and CE, but the trend does not suggest that
CE is merely a percentage of anti-CK-stained cells. This
further suggests that diﬀerent phenotypic populations of
CTC are present within these samples, possibly related to
other physiological factors.
4. Discussion
In this report, we describe a platform to capture and detect
the heterogeneous phenotypes of tumor cells that may exist
in patient samples. CTCs were isolated from buﬀyc o a t s
using the EpCAM antibody, or with mixtures of antibodies.
Universal detection of speciﬁcally captured cells was based
on CEE-Enhanced (CE) for in situ labeling of the capture
antibodies bound to the surface of the captured CTCs within
the microchannel. CE costained all CK-positive cells and
could be used to enhance the intensity of the CK-stained
cells, or to detect cells without CK stain (Figures 5 and 6).
Control blood from healthy volunteers showed no positive
cells with either anti-CK or CE.
The use of antibody mixtures and CE showed that
additional EpCAM-negative and CK-negative tumor cells
were present in peripheral blood. Since both immuno-
capture and immuno-detection are antigen-concentration-
dependent, the term “negative” here indicates those cells that
may contain some antigens, but are below the threshold for
either capture or detection employed in this study. Table 2
shows that CTCs captured with anti-EpCAM alone and
stainedforCKandCE,containedapopulationoftumorcells
that was not CK-positive. Likewise, additional CK positive
cells could be identiﬁed when a mixture of antibodies was
used for capture instead of EpCAM alone. The highest
numbers of identiﬁed cells were seen when an antibody
mixture was used for capture in combination with CE to
detect those additional cells that contained very low levels of
e i t h e rE p C A Mo rC Ko rb o t h .
The loss of EpCAM or CK in tumor cells has been
extensively described. It is not always clear whether the loss
of CK is a function of independent oncogenic processes [26–
28] or always related to EMT [2, 29]. The present study
was focused on detection of CTCs that did not containJournal of Oncology 7
(a) (b) (c)
Figure 5: The use of CEE-Enhanced to improve detection of cells on the microchannel. (a) A clinical breast cancer CTC stained for CK
and nuclear-stained with DAPI. This cell is weakly CK positive. (b) The same cell after subsequent stain with CE labeled with the same
AlexaFLuor-488 ﬂuorophore in order to enhance the stain intensity. (c) SKOV cell spiked into blood and recovered on the microchannel
using an antibody mixture (see Section 2). Cells on the channels were stained with CE-488 and DAPI. The four WBCs stained blue for DAPI
only, while the SKOV (attached to post) can be detected only with CE (green). This higher contrast image shows the outline of the posts in
themicrochannel. Together theseimages showthatCEcanbeusedtoaugment weakly stainingCKcells orcanbeusedtodetectcells without
CK stain.
(a) (b) (c)
(d) (e) (f)
Figure 6: Costaining clinical lung cancer CTCs with anti-CK and CEE-Enhanced. (a–c) A single CTC on the microchannel stained with
anti-CK (a), CE-AlexaFluor-546 (orange, (b)), and (c), a composite image. (d–f) shows the same order of staining but with 2 attached CTCs.
This demonstrates the costaining of the internal CK antigen and the cell surface antigens with CE.8 Journal of Oncology
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Figure 7: Clinical breast cancer samples sequentially stained with
anti-CK and with CEE-Enhanced. The antibody mixture was used
tocaptureCTCs.Thedarkbarsonthebottomrepresentthenumber
of CK positive cells detected in a sequential series of stage IV breast
cancer samples. The location of these cells was recorded and then
the channel was restained with CE. The light bars on top represent
the newly detected CTCs after CE stain. All cells designated as
positive were CD45 negative and DAPI positive.
either EpCAM or CK. CK can occasionally be aberrantly
expressed in lymphocytic cells, though CD45 is used to
rule out the CK-positive lymphocytes. Aberrant expression
of CK in bone marrow appears to be more common
than in peripheral blood [30], and expression caused by
inﬂammatory processes can also contribute to CK false
positives [31]. Similar issues surround the upregulation and
down-regulation of EpCAM, with similar consequences for
the isolation or detection of CTCs in bone marrow or
periperal blood. It seems well established that EpCAM is
found frequently in tumors [23]; that it can be up-regulated
in tumors and has been associated with poor prognosis [24].
From the CTC isolation perspective it is not the ﬁnding of
CTCs that have expressed EpCAM that is in question, but
the concern over false negatives in the failure to detect CTCs
that do not express EpCAM. Aside from the fact that not all
tumors express EpCAM, there are issues of down-regulation
of adhesion molecules in order to metastasize and migrate
[25, 32] and the programmed down-regulation of EpCAM
as part of EMT [2, 29]. Moreover, EpCAM can be lower as a
result of chemotherapy and so CTC enumeration may vary
as a result of treatment [33].
Itisforthesereasonsthatwedevelopedasystemtoenrich
cells with or without EpCAM and integrated this with an
in situ labeling approach that ﬂuorescently labels those cells
with bound capture antibody. Within a biological system
containing such a heterogeneous genotypic etiology it may
be diﬃcult or impossible to predict with any certainty what
kinds of tumor cells might be present in any given sample. If
one attempts to apply speciﬁcity to the kinds of cells being
enriched from a population by using antibodies, it makes
sense to visualize the very targets of that enrichment. With
heterogeneous samples, one sample may contain mostly
EpCAM-positive cells, while the next may have a diﬀerent
phenotype or range of phenotypes. Ancillary tumor-speciﬁc
markers may then be used to conﬁrm that they are indeed
tumor cells or to measure tumor-speciﬁc mutations. In
this limited study two biopsy-conﬁrmed Her2/neu-positive
samples from Figure 7 were found to contain ampliﬁed
Her2/neu signals in the CTCs that stained with CE-only,
in addition to CK-positive cells. Thus CE may be used to
identify a wider population of CTCs for further study than
would normally be identiﬁed with anti-CK alone.
Isolation of CTCs from metastatic breast cancer samples
using an antibody mixture showed additional CE-positive
cells and that the numbers were not proportional to the
endogenous levels of cells identiﬁed by anti-CK staining
(Figure 7). While it is desirable to detect more CTCs, the
real value of alternate detection using CE may be as much
qualitative as quantitative. The proportion of CK-negative or
EpCAM-negative CTCs may provide additional diagnostic
insights, at very least by suggesting the levels of CTCs that
haveundergoneEMTinagivensample.Specializedantibody
mixtures directed to new cancer markers could be developed
to enhance the detection of speciﬁc populations of CTCs.
Since the number and type of CTCs is dependent on
the isolation and detection technology, it is unlikely that
numerical values or cutoﬀso b t a i n e db yC e l l S e a r c hw i l lb e
the same for another system. Unlike serum markers, there is
no absolute scale for standardization of cell detection across
platforms, but rather an individual standard tied directly to
as p e c i ﬁ ce n r i c h m e n ta n dd e t e c t i o nf o r m a t .T h e r ei saw i d e
range of reported values, ranging from numbers roughly
comparable to CellSearch to numbers in the hundreds and
thousands per mL of blood [6, 10]. Timing is another
consideration with regards to enumeration. CTCs isolated as
point-of-care within a few hours of blood draw [6, 34]m a y
be the most desirable, though possibly the most challenging
approach for widespread use. The half-lives of CTCs in
circulation are generally considered to be less than 24h,
possibly only a couple hours [35], though half-lives of
days and months have also been reported [36]. The times
of collection and storage are signiﬁcant considerations for
enumeration comparisons.
With regards to improved prognostic forecasting it may
be of limited value to simply ﬁnd higher numbers using anti-
EpCAM, thus merely resetting the cutoﬀ range of signiﬁ-
cance. Earlier processing or automated systems with higher
sensitivity thresholds resulting in higher CTC values may not
necessarily improve prognostic value beyond that achieved
by CellSearch. One interesting study in this regard measured
all anti-EpCAM and anti-CK-positive “objects” isolated
by the CellSearch system [37]. Multiple types of cellular
particles and fragments were found to perform equivalently
to the classically deﬁned intact CTC in predicting survival.
This would suggest that this system would be quite robust
at its current level of prognosis, regardless of user bias,
since ancillary observations support the same trend. It is
in this robustness that the limitations emerge. Systems with
associated redundancies reinforce a strong general trend, but
by their very nature do not lend themselves to improved
speciﬁcity.Journal of Oncology 9
Given the heterogeneity of circulating epithelial cells,
most of which are assumed to be circulating tumor-
associated epithelial cells, the question of detection speci-
ﬁcity has not been well studied beyond the parameters of
EpCAM and CK. Questions of EMT and the role of these
cells at diﬀerent stages of cancer is of intense interest. Studies
in our lab have shown the majority of curable Stages I–III
breast cancer samples have signiﬁcant levels of CE-stained
cells but few CK-positive cells (manuscript in preparation).
Additional studies are underway.
5. Conclusions
The current study demonstrates that the peripheral blood
of cancer patients contains circulating tumor cells other
than those normally detected with antibodies to EpCAM
and cytokeratin. The use of CEE-Enhanced and antibody
mixtures along with the traditional anti-EpCAM and anti-
CK-based approach may lead to new insights into the
diagnostic applications of CTCs.
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